Американское общество гирудотерапии

Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps

Retrospective study published in Microsurgery (2018)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyКлинические исследованияРазработка лекарственных препаратовHarun A et al. · Microsurgery, 2018

Abstract

OBJECTIVES: The goal of this study was to review the feasibility of local bivalirudin injection for adjunct treatment of venous congestion of head and neck reconstructive flaps. METHODS: A retrospective chart review of patients who underwent bivalirudin treatment for venous congestion of head and neck reconstructive flaps in a single institution from September 1, 2012 to September 1, 2015 was undertaken. Individuals were treated with variable number of intradermal injections directly into the flap followed by a small skin incision to allow extended passive bleeding. The main outcome measure was improvement of flap congestion. RESULTS: Ten patients with free flap reconstruction (4 anterolateral thigh flaps, 2 pectoralis major flaps, 2 fibula osseocutaneous flaps, 1 supraclavicular flap, and 1 radial forearm free flap) of various head and neck defects underwent treatment with bivalirudin. Bivalirudin injections were utilized as adjunct therapy in 6 patients. Two individuals underwent alternate therapy for venous congestion immediately following injection and therefore the efficacy could not be assessed. Of the 8 remaining flaps, 4 developed partial necrosis, and 1 developed complete necrosis requiring additional reconstruction. Two individuals required blood transfusions during bivalirudin treatment. CONCLUSIONS: Bivalirudin is a safe and feasible adjunct therapy for treatment of flap congestion. It may serve as a useful alternative to traditional leech therapy, as bivalirudin negates the need for antibiotic prophylaxis, eliminates the psychological aversion associated with leech therapy, and avoids the potential for leech migration. Further work to determine the efficacy of bivalirudin to standard leech therapy is warranted.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal Article
Indexed MeSH termsAdultAgedAged, 80 and overAntithrombinsCombined Modality TherapyFemaleFree Tissue FlapsHead and Neck NeoplasmsHirudinsHumansHyperemiaLeeching

Резюме

Single-institution retrospective study of 10 patients with bivalirudin local-injection for venous congestion of head-and-neck free flaps. 8/10 flaps assessable; 4 partial-necrosis, 1 complete-necrosis. Bivalirudin negates need for antibiotic prophylaxis.

Почему это важно для гирудотерапии

This retrospective chart review assessed local bivalirudin injection as adjunct treatment for venous congestion of head and neck reconstructive flaps in 10 patients. Of 8 assessable flaps, 4 developed partial necrosis and 1 complete necrosis, with 2 patients requiring transfusions. The authors concluded bivalirudin is safe and feasible and may serve as a useful alternative to traditional leech therapy by avoiding antibiotic prophylaxis, psychological aversion, and leech migration. This is relevant to ASH's domain as it positions a hirudin-related anticoagulant relative to medicinal leech therapy in flap congestion management. The honest caveat is that this is a small uncontrolled series, efficacy could not be assessed in 2 patients, no head-to-head comparison with live leech therapy was conducted, and the authors explicitly call for further work to determine comparative efficacy.

Цитирование

Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps.

Harun A et al. · Microsurgery, 2018

Связанный клинический контекст

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.